论文部分内容阅读
目的:基于对重组牛碱性成纤维细胞生长因子滴眼液(贝复舒)治疗眼角膜上皮缺损的成本-效果分析基础上,进行上市后的预算影响分析。方法:采用多中心非随机同期对照试验设计收集原始数据,采用增量成本效果分析对其成本-效果进行评价,然后进行预算影响分析。结果:贝复舒治疗组相对于对照组,每增加1个效果单位,成本可节约11.72元。在住院病例中,贝复舒治疗眼角膜缺损主要通过直接降低住院费用和提高治疗效果并降低住院时间两条路径降低患者的住院费用。结论:贝复舒滴眼液治疗眼角膜上皮缺损是有效、安全、经济的。
OBJECTIVE: Based on the cost-effectiveness analysis of recombinant human bovine basic fibroblast growth factor eye drops (Beifu Shu) in the treatment of corneal epithelial defects, the post-IPO budget impact analysis was carried out. Methods: A multicenter, non-randomized, controlled trial design was used to collect raw data and cost-effectiveness analysis was used to evaluate its cost-effectiveness. Then, budget impact analysis was performed. Results: Beifu Shu treatment group relative to the control group, for each additional unit of effect, the cost savings of 11.72 yuan. In hospitalized cases, Beifu Shu for the treatment of corneal defects mainly by reducing the cost of hospitalization and improve the treatment effect and reduce the length of hospital stay in two ways to reduce the cost of hospitalization. Conclusion: Beifu Shu eye drops treatment of corneal epithelial defects is effective, safe and economical.